Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi

Haematologica. 2016 Feb;101(2):e66-8. doi: 10.3324/haematol.2015.132811. Epub 2015 Oct 15.

¹ Department of Diagnostics, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Italy [email protected].
² Department of Internal and Experimental Medicine, University of Pisa, UO Hematology, Italy.
³ Department of Nuclear Medicine, Arcispedale S. Maria Nuova - IRCCS of Reggio Emilia, Italy.
⁴ Department of Medicine, University Hospital and School of Medicine, Universidade Federal do Rio de Janeiro, Brazil.
⁵ Hematology Unit, Spedali Civili di Brescia, Italy.
⁶ Division of Hematology, Department of Hematology and Oncology, Niguarda Hospital, Milan, Italy.
⁷ Hematology Unit, Arcispedale Santa Maria Nuova, IRCCS of Reggio Emilia, Italy.
⁸ Department of Diagnostics, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Italy.

No abstract available

Keywords: FDG-PET; follicular lymphoma; minimal residual disease; nuclear medicine; progression-free survival.

Publication types